Spero Therapeutics
Biotechnology, 675 Ave, Cambridge, Massachusetts, 02139, United States, 11-50 Employees
Phone Number: 85********
Who is SPERO THERAPEUTICS
We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resis...
Read More
-
Headquarters: 675 Massachusetts Ave, Cambridge, Massachusetts, 02139, United States
-
Date Founded: 2013
-
Employees: 11-50
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
-
CEO:
Ankit Mahadevia
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from SPERO THERAPEUTICS
Spero Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Spero Therapeutics
Answer: Spero Therapeutics's headquarters are located at 675 Ave, Cambridge, Massachusetts, 02139, United States
Answer: Spero Therapeutics's phone number is 85********
Answer: Spero Therapeutics's official website is https://sperotherapeutics.com
Answer: Spero Therapeutics's revenue is $100 Million to $250 Million
Answer: Spero Therapeutics's SIC: 2834
Answer: Spero Therapeutics's NAICS: 325412
Answer: Spero Therapeutics has 11-50 employees
Answer: Spero Therapeutics is in Biotechnology
Answer: Spero Therapeutics contact info: Phone number: 85******** Website: https://sperotherapeutics.com
Answer: We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Speros lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Speros partnership directed programs consist of SPR206 and tebipenem HBr, which through the companys business development efforts, have joint venture relationships supporting their ongoing development. SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting. Tebipenem HBr, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, or cUTIs, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month